Update on Sale of Invictus BioPharma
Sydney, Dec 21, 2022 AEST (ABN Newswire) - On 5 April 2022, the Directors of VGI Health Technology Limited (
NSX:VTL) announced the sale of its wholly owned subsidiary, Invictus BioPharma Pty Ltd to Invictus BioPharma Holdings Ltd (IVBHL) (the Transaction).
Shareholders of VTL subsequently approved the transaction at a general meeting held on 3 June 2022.
To enable the Transaction to be completed, VTL and IVBHL have agreed to extend the Sunset Date from 31 December 2022 to 31 March 2023.
About VGI Health Technology Limited
VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
| ||
|
